Dermatologist-led androgen intelligence
DHT support is not a single product and not a universal solution. It is a sequence: recognise the pattern, confirm what is actually driving it, choose a level of intervention you can sustain, and keep it under review. Follicular sensitivity, scalp condition, medical history, treatment suitability and long-term adherence all sit inside that sequence. A bottle does not.
Not every hair fall is androgen-related. This page will tell you where the prescription boundary sits, what a cosmetic product can and cannot do, and when the correct next step is assessment rather than another purchase.
Quick answer
DHT support refers to a personalised combination of medical evaluation, appropriate treatment, scalp care, supportive products and progress monitoring for people whose hair thinning may involve androgen sensitivity. It does not mean that every hair-loss product blocks DHT, and it does not mean that every form of hair fall is androgen-related. The most useful thing this page can do is help you work out which of those two statements applies to you before you spend anything.
Medically reviewed by Dr. Amit S. Agarkar, MBBS, MD Dermatology, FCPS, DDV — Consultant Dermatologist, Trichologist and Hair Restoration Surgeon. Reviewed 29 July 2026 · Next review 29 January 2027.
Four ideas do most of the work on this page. If you take only these away, you will already choose better than most people shopping this category.
Dihydrotestosterone is an androgen produced from testosterone by the enzyme 5-alpha-reductase. It has normal jobs in the body. Having it is not a disease, and a blood level of it is not what decides whether your hair thins.
Patterned hair loss is driven by how strongly particular follicles respond to androgens. MedlinePlus Genetics describes variations in the androgen receptor gene that appear to make receptors more easily stimulated — and states plainly that it is still unclear how those changes translate into risk.
An umbrella term covering prescription medicines, prescription topicals, growth-support treatments, scalp care, nutritional support where clinically indicated, cosmetic density products, and the monitoring that holds them together. Only some of those act on the androgen pathway.
None of it is a diagnosis. A shampoo is not a substitute for prescription therapy. A supplement does not correct receptor sensitivity. A cosmetic fibre does not change a follicle. Saying so is not modesty — it is the difference between a plan and a purchase.
Every line below is a claim that appears routinely in this category. None of them appears on this page as a statement of fact, and the list is published so you can hold us to it.
Five stages, each one selectable. This is a simplified pathway: follicular genetics, receptor sensitivity, age, sex, local scalp biology and other factors all influence the outcome, and the diagram cannot show them.
Testosterone circulates in everyone, at different levels by sex, age and individual physiology. On its own it is not the molecule most closely associated with patterned scalp thinning. It is the substrate for the step that follows.
What this stage does not tell you: A testosterone level is not a hair-loss test. Ordering one because your hair is thinning, with no other clinical reason, usually answers a question nobody asked.
This enzyme converts testosterone into DHT. It exists as more than one isoenzyme, distributed differently around the body. The prescribing information for one oral 5-alpha-reductase inhibitor describes the type predominant in skin including the scalp, and the type found in hair follicles, prostate and elsewhere — which is why a medicine that inhibits this step has effects beyond the scalp.
What this stage does not tell you: This is the step prescription 5-alpha-reductase inhibitors act on. It is also why those medicines are not casual purchases: an enzyme with jobs elsewhere in the body is being inhibited elsewhere in the body too.
DHT binds the androgen receptor more strongly than testosterone does. It is present in everyone with normal androgen physiology and it is not, by itself, a pathology. What differs between people is what happens next.
What this stage does not tell you: A high DHT level is not the usual explanation for patterned thinning, and a normal one does not rule it out. This is the single most common misunderstanding in the category.
DHT acts by binding androgen receptors inside follicle cells. Susceptible follicles respond to that signal in a way that shortens the growing phase over successive cycles. MedlinePlus Genetics describes receptor-gene variations that appear to make receptors more easily stimulated — and is explicit that how this raises risk remains unclear.
What this stage does not tell you: Two people can have the same DHT and completely different hair. The variable is here, not upstream. It also means “lowering DHT” and “blocking the receptor” are different interventions that some marketing treats as one.
Affected follicles produce progressively finer, shorter, less pigmented hairs across cycles. Because susceptibility is regional, this shows up as a pattern — temples, mid-scalp, crown — while the back and sides usually behave normally. The pattern is the diagnostic signal, not the amount coming out in the shower.
What this stage does not tell you: Miniaturised is not the same as gone, and it is not the same as dormant. How much is recoverable depends on how far the process has gone, which is exactly why timing and assessment matter more than product choice.
A pattern is a clue, not a diagnosis. The left column describes features commonly associated with androgenetic hair loss. The right column describes features that usually mean something else is going on — and the right column is the more important one, because it is the one people skip.
Features often present when androgen sensitivity is part of the picture. Several together are more meaningful than any one alone.
Any of these deserves assessment rather than a product search. Some are urgent. The American Academy of Dermatology sets out the distinction between hair shedding and hair loss, and it is the distinction that most often gets missed.
Eight questions, answered in your browser. Nothing is sent anywhere, no account is needed and no API is called. What comes back is a specification — categories, sequence and cautions — that you can take to a dermatologist. It deliberately cannot name a product, a brand, a strength or a price.
This tool is deterministic: the same answers always produce the same output, and no randomness is used anywhere in it. It applies general rules to categories. It does not examine your scalp, it does not know your medical history, and it cannot tell you what you have. Where your answers touch a prescription or a safety question, it will say so and stop rather than continue.
Seven categories sit under “DHT support”. They are not interchangeable, they do not all act on the same thing, and only some of them act on the androgen pathway at all. Each card says which.
Oral 5-alpha-reductase inhibitors reduce the conversion of testosterone to DHT. They may be considered for selected patients after evaluating suitability, contraindications, reproductive plans, potential adverse effects and the monitoring that goes with them. This page names no dose, no schedule and no product, because those belong in a consultation and nowhere else.
Understand Prescription SafetySome topical approaches are prescription-controlled or are prescribed as part of a wider plan, including combination products where a second active is present. Careful use and medical oversight still apply — a topical route does not make a prescription molecule a cosmetic.
Explore Topical Treatment GuidanceHair-growth support and DHT-pathway management are related but not identical. The best-established topical growth treatment does not act on the androgen pathway at all — it works on the growth cycle. Grouping everything under “DHT” hides that difference, and the difference is the reason two products can both help and neither replace the other.
Explore Hair-Growth TreatmentsShampoos can genuinely help with cleansing, oil control, flaking and overall scalp comfort, and a comfortable scalp is a better platform for anything else you do. What a rinse-off product cannot be presented as is the equivalent of prescription DHT-directed therapy. Contact time alone makes that a difficult claim to sustain.
Shop DHT-Support ShampoosAnti-dandruff care, gentle cleansing, barrier support and inflammation-aware routines. This category will not change androgen signalling, and it is still worth getting right — persistent itch, scaling or soreness both interferes with treatment and is often the actual reason someone came looking.
Build a Scalp-Support RoutineIron, vitamin D, zinc, vitamin B12, folate and protein intake are considered against diet, symptoms, laboratory findings and professional advice — not marketed as androgen-pathway agents by default. Correcting a genuine deficiency can matter a great deal. Taking a supplement you do not need does not, and some nutrients cause harm in excess.
Explore Hair NutritionHair fibres, scalp concealers, root camouflage and volumising styling change what the scalp looks like today. They do not treat the underlying process and they are not pretending to. Wanting to look the way you want to look while a longer plan runs is a perfectly reasonable thing, as long as the two are not confused.
Explore Instant Density Solutions
The filter set below is live and the grid is deliberately empty. HairsnCares does not publish a product name, price, pack size, rating or availability that has not been verified against the manufacturer’s own source. When verified data is loaded, these cards populate; until then an honest empty state is better than a convincing placeholder.
The product array behind this grid is documented and empty. Its render guard rejects any entry that does not declare a name, a category, a prescription status and a net quantity — the four fields we would otherwise have to invent. That guard is why an incomplete record cannot reach this page even if the array is populated carelessly. The full catalogue is on the shop, where inventory and pricing are live.
No star ratings, review counts, bestseller badges, stock-scarcity messages, countdown timers or delivery promises appear anywhere on this page. Prescription items, where they exist, remain subject to applicable requirements and professional review and are not sold as ordinary ecommerce lines.
Twelve ingredient families, each with an evidence label and an explicit statement of what it cannot claim. They are not all DHT blockers, and grouping them as though they were is how this category loses people’s trust.
Shampoo, medicated
Shampoo, serum, tonic
Supplement, shampoo, serum
Supplement, oil
Shampoo, medicated
Shampoo, tonic
Shampoo, pre-wash, scalp treatment
Serum, shampoo, conditioner
Serum, ampoule
Serum, tonic
Ampoule, tonic
Shampoo, oil, tonic
Nine phrases you will meet on this shelf, and the question each one should prompt. None of these is necessarily dishonest — they are just doing less work than they appear to.
Nine approaches against nine questions. The column that settles most arguments is the third one: whether the approach acts on the androgen pathway at all.
| Approach | Primary role | Prescription required | Acts on androgen pathway | Supports growth environment | Cosmetic density benefit | Time horizon | Key limitations | Medical oversight |
|---|---|---|---|---|---|---|---|---|
| Oral prescription therapy | Reduces DHT formation at the enzyme step | Yes | Yes | Indirectly | No | Long-term | Systemic effects, reproductive precautions, not for everyone | Essential |
| Topical prescription therapy | Applied locally as part of a supervised plan | Yes | Depends on the active | Yes | No | Long-term | Application burden, local irritation, combination products carry the second active’s risks | Essential |
| Topical growth-support treatment | Acts on the growth cycle, not the androgen pathway | Varies by market | No | Yes | No | Long-term | Not a DHT-directed treatment; benefit is lost if stopped; early shedding phase possible | Recommended |
| Anti-dandruff or scalp shampoo | Cleanses and controls flaking and itch | Some are | No | Supports the environment | No | Ongoing | Rinse-off contact time; treats the scalp surface, not the process underneath | Optional |
| Nutritional support | Addresses a deficiency or an identified need | Usually not | No | Only if a deficiency exists | No | Depends on the deficiency | No benefit without a genuine need; several nutrients are harmful in excess | Assess first |
| Cosmetic hair fibres and concealers | Makes existing hair look denser today | No | No | No | Immediate | Same day, washes out | Purely visual; no effect on the follicle; can transfer onto clothing and pillows | Not required |
| Volumising styling products | Changes how hair sits and reflects light | No | No | No | Immediate | Same day | Cosmetic only; heavy or frequent product with poor removal can irritate the scalp | Not required |
| Low-level light devices | Home or clinic light-based devices | Varies by device | No | Under study | No | Months of consistent use | Evidence and device quality vary widely; not everyone responds; cost is front-loaded | Recommended |
| Clinical procedures | In-clinic procedures and hair restoration surgery | Clinician-performed | No | Varies | Varies | Planned course, then maintenance | Operator-dependent; surgery redistributes hair and does not stop the process in hair that was not transplanted | Essential |
Every cell is a category statement, not a statement about a specific product. Two shampoos in the same row can behave completely differently, and a combination prescription product carries the risks of every active in it, not only the one named on the front. Nothing in this table tells you which row applies to you.
Male-pattern presentations are the most recognisable version of this process, which is both why they are diagnosed earlier and why they are self-treated more carelessly.
Because the pattern is recognisable, men frequently skip assessment and go straight to a purchase. The cost of that is not the money. It is the years spent on a product that was never going to act on the mechanism, during which a treatable process continues.
Oral 5-alpha-reductase inhibitors are prescription medicines with a documented adverse-effect profile, including effects on sexual function reported in the prescribing information, and with implications for prostate-specific antigen testing that your doctor needs to know about. Some men take them for years without difficulty; some do not tolerate them; a few report effects that persist after stopping. That range is exactly why the decision belongs to a consultation.
This page names no dose, no schedule and no product. Not because the information is secret, but because a page cannot examine you, cannot screen you and cannot follow you up.
Female pattern hair loss is not the female edition of male-pattern baldness, and this page refuses to present it as one. The clearest evidence for that sits in the labelling of the best-known medicine in the category.
The American Academy of Dermatology notes that other causes of hair loss can look like female pattern hair loss and need to be ruled out, and that more than one treatment is often combined. Iron status, thyroid function, polycystic ovary syndrome, recent pregnancy, rapid weight change and medication effects all belong in that assessment. MedlinePlus Genetics also records the association between androgenetic alopecia in women and polycystic ovary syndrome.
The prescribing information for the best-known oral 5-alpha-reductase inhibitor for hair loss, as published on DailyMed by the US National Library of Medicine, states that it is indicated for male pattern hair loss in men only and is not indicated for use in women. It also reports a study in postmenopausal women with androgenetic alopecia in which effectiveness could not be demonstrated against placebo across hair counts, patient self-assessment, investigator assessment or photographic rating.
That is why “DHT support” cannot be sold as one symmetrical category to both sexes. Women’s patterned thinning is managed with a different set of considerations, and any page that hands a woman the men’s answer is not being helpful.
Thirteen questions that change what should happen next. Any one of them turning up an answer is a reason to speak to a clinician before you buy anything.
Several treatments in this category are contraindicated or simply unstudied in pregnancy and breastfeeding. Tell your clinician before any product is discussed, and include products already in the house that belong to someone else.
This applies to both partners and to plans, not only to current pregnancy. Reproductive considerations are one of the main reasons a prescription decision in this category is revisited rather than made once.
Handling precautions for certain oral tablets apply to anyone who may become pregnant, whether or not they are the patient. Intact coated tablets are handled normally; crushed or broken ones are not.
Bring the full list, including anything bought without a prescription, herbal products and supplements. Interactions in this category are more often with supplements than people expect.
Polycystic ovary syndrome, thyroid disease and other endocrine conditions change both the differential diagnosis and the treatment options. They are a reason to be assessed, not a reason to avoid assessment.
Some medicines used in this area are metabolised in the liver, and the prescribing information advises caution where liver function is abnormal. Your clinician needs to know.
Describe what happened, how quickly, and what you did. A previous reaction changes what should be tried next and how it should be introduced.
This is not the presentation this page is about. Rapid, diffuse or patchy loss needs assessment promptly rather than a product trial.
Redness, pustules, weeping, crusting, pain or burning should be treated as a skin problem first. Applying actives to inflamed skin usually makes both problems worse.
Areas where the skin looks smooth and follicle openings appear lost may indicate a scarring alopecia. These are time-critical, because loss in scarred areas is permanent.
Hair loss under 18 needs assessment rather than an over-the-counter routine, and several prescription options are not indicated in this age group at all.
Follow your surgeon’s instructions and get specific clearance before introducing anything new. Surgery redistributes existing hair; it does not switch off the process in the hair that was not transplanted.
Tests are ordered because a history and examination raised a question — not as a routine preliminary to buying a shampoo. Ordering a panel yourself usually produces numbers without a question to attach them to.
This page deliberately publishes no week counts of its own. Timelines vary by person, by treatment and by market, and a number printed on a webpage gets read as a promise. What follows is the sequence of stages and what each one is for; your clinician sets the dates.
Standardised photographs, the pattern recorded, scalp examined, treatment history taken and safety screening completed. Everything after this is measured against this point, so a vague baseline costs you the ability to judge later.
The only variable in the early phase is whether the routine actually happens. Visible density change is not expected yet, and looking for it daily is the fastest route to abandoning something that had not been given a chance.
The first review is about tolerance and sustainability rather than efficacy. Shedding pattern, scalp comfort, side effects and whether you are actually using it as agreed.
Standardised photographs compared side by side against baseline, hair calibre, density appearance and your own reported change. This is the first point at which the question “is this working” can be answered with anything other than an impression.
Where a treatment is working, the benefit generally depends on continuing it. The prescribing information for one oral option states that withdrawing treatment leads to reversal of the effect within a year. A plan that has no maintenance phase is a plan with an expiry date on it.
The prescribing information for one oral 5-alpha-reductase inhibitor, as published on DailyMed, states that in general daily use for three months or more is necessary before benefit is observed, that continued use is recommended to sustain benefit, and that withdrawal of treatment leads to reversal of the effect within a year. We report those as label statements about that product, with a verification date, rather than converting them into a HairsnCares timeline that would then be applied to products they were never written about. That is US labelling; products marketed in India carry their own approved labelling, and yours may differ.
Hair changes slowly enough that memory is a poor instrument and the bathroom mirror is a worse one. Nine fields, photographed and recorded the same way every time, will tell you more than any subjective impression.
The imagery standard we hold ourselves toEvery photograph used for comparison should use the same camera and lens, the same distance, the same lighting, the same hair length and styling state, and no retouching of any kind. Where a photograph is published, it needs written and revocable consent. HairsnCares publishes no before-and-after gallery on this page: we would rather show an empty framework and the standard than a set of images you have no way to verify.
Medical review is only meaningful if the scope of the review is stated, including what it does not cover.
This page is designed to help consumers distinguish between established treatment pathways, supportive scalp and haircare, nutritional considerations and cosmetic density products. DHT-related hair loss requires pattern assessment and safety evaluation rather than reliance on a single shampoo, supplement or marketing claim.
What this review covered. The accuracy of the biology described, the separation between medical and cosmetic claims, the safety content, the refusal to publish doses or timelines, and the wording of every statement about what a product can and cannot do.
What it did not cover. Your hair and your scalp, which have not been examined. Any individual product sold on this site or elsewhere. Pricing or availability. Nothing here is a prescription, and review of a page is not a recommendation of a product to a person.
Commercial disclosure: HairsnCares sells haircare products, and Dr. Agarkar is associated with HairsnCares. That relationship is why the claim limits on this page are published rather than assumed.
Everything on this page assumes androgenetic hair loss, which is gradual, patterned and not painful. The signs below do not fit that picture, and several of them are conditions where the follicle is lost permanently if treatment is delayed.
Same day, or as soon as you can be seen
Worth being examined, not worth panicking about
Supportive haircare cannot distinguish between these causes, and neither can a questionnaire. That is a diagnosis, and it needs someone who has examined your scalp.
Twenty-eight questions across seven categories. Search the answers or filter by topic.
Dihydrotestosterone is an androgen produced from testosterone by the enzyme 5-alpha-reductase. It binds androgen receptors more strongly than testosterone does and has normal roles in the body. Everyone with typical androgen physiology makes it, so having DHT is not in itself a problem.
No. Patterned hair loss is more closely related to how strongly particular follicles respond to androgens than to how much DHT is circulating. Two people with similar levels can have completely different hair. This is why a DHT blood level is rarely the useful test people expect it to be.
It describes how strongly a follicle reacts to the androgen signal it receives. MedlinePlus Genetics describes variations in the androgen receptor gene that appear to make receptors more easily stimulated by androgens, and states that it remains unclear exactly how those changes translate into hair-loss risk. Sensitivity is regional, which is why loss appears in a pattern.
No, and this is the most important thing on the page. Telogen effluvium after illness, surgery, fever, childbirth or rapid weight loss, alopecia areata, scalp disease, traction from tight styling, nutritional deficiency, thyroid disease and scarring alopecias all cause hair loss and none of them is androgen-driven. More than one can run at the same time.
Shedding is hair coming out at the root, often suddenly and diffusely, and it commonly follows a trigger by a couple of months. Patterned loss is a gradual reduction in hair calibre in specific regions, with the back and sides usually spared. The American Academy of Dermatology publishes a clear consumer explanation of the distinction, and it is worth reading before you buy anything.
That is a decision for a clinician who has taken a history and examined you. Tests are ordered to answer a question raised by the assessment. Ordering a panel on your own usually produces numbers with no question attached to them, and normal results do not rule out patterned hair loss.
It depends entirely on which category it is in. A prescription oral medicine acts on the enzyme step. A medicated shampoo acts on scalp condition. A supplement addresses a deficiency if one exists. A cosmetic fibre changes what the scalp looks like today. The phrase covers all of these, which is precisely why it needs unpacking.
A shampoo is a rinse-off product with limited contact time, and any claim of that kind would need penetration, concentration and clinical effect to be established for that specific formulation. Shampoos can genuinely help with cleansing, oil control, flaking and comfort. Presenting that as equivalent to prescription DHT-directed therapy is not supportable.
We make no regrowth claim for any shampoo. A shampoo that controls flaking and itch makes the scalp a better environment for whatever else you are doing, and that is a real benefit. It is not the same as regrowth, and if a pack promises regrowth you should ask which study says so.
As a category, no. Some botanicals have laboratory or mechanistic interest behind their inclusion; the evidence in patterned hair loss remains limited or inconclusive for most of them. Natural describes an origin, not a mechanism, and several botanicals interact with medicines.
Often yes, and many plans do combine categories that act on different things. The two risks are stacking multiple products containing the same active without realising, and adding several new things at once so that you cannot tell which one caused a benefit or a reaction. Introduce changes one at a time and tell your clinician the full list.
Used as directed on a healthy scalp they are cosmetic products and generally well tolerated. They do not treat anything, they can transfer onto clothing and bedding, and they should be kept off broken, inflamed or recently operated skin. If you are using them daily to hide a change you have not had assessed, the fibres are not the problem to solve.
Before you commit to years of anything, and immediately if you have sudden diffuse shedding, patches, scalp pain, burning, pustules, severe scaling, shiny or scarred-looking areas, loss of eyebrows or eyelashes, hair loss with systemic symptoms, or hair loss under 18. Scarring conditions in particular are time-critical, because loss in scarred skin is permanent.
They are prescription medicines with documented benefits and documented adverse effects, which is exactly why they are prescription medicines. The prescribing information records effects on sexual function, implications for prostate-specific antigen testing, and contraindications in pregnancy. Whether the balance is right for you is a decision only a clinician who has assessed you can help you make.
Because a page cannot examine you, screen you for contraindications or follow you up afterwards, and because dose and product vary by country, formulation and individual. Publishing a number would invite self-medication with no safety net. The categories are explained in full so that you arrive at a consultation informed rather than already committed.
It depends on the supplement, the dose and you. Some nutrients are harmful in excess, several interact with prescription medicines, and taking a supplement for a deficiency you do not have provides no benefit. Tell your clinician about everything you take, including anything bought without a prescription.
They can contribute to hair loss and can coexist with patterned thinning, which is one reason assessment matters. Correcting a genuine deficiency can make a real difference. Assuming a deficiency and treating it blind usually does not, and can cause harm where the nutrient is one that accumulates.
Yes. Female pattern hair loss is common and is included under androgenetic alopecia. It usually presents as a widening central part and reduced density with the frontal hairline preserved, rather than as the recession and vertex loss seen in men.
Not automatically. The prescribing information for the best-known oral 5-alpha-reductase inhibitor states that it is indicated in men only and is not indicated for use in women, and reports a study in postmenopausal women in which effectiveness could not be demonstrated. Women's patterned thinning is managed with a different set of considerations and a wider differential diagnosis.
That is a question for your clinician, and it should be the first thing you tell them. Several treatments in this area are contraindicated or unstudied in pregnancy and breastfeeding. Postpartum shedding is also very common and is usually a different process that resolves on its own timescale.
If your history or examination suggests it. MedlinePlus Genetics records an association between androgenetic alopecia in women and polycystic ovary syndrome, and thyroid disease is a recognised contributor to hair loss. Whether to test is a clinical decision, not a routine step before buying shampoo.
Longer than most people expect, and this page publishes no timeline of its own because it varies by person, treatment and market. As one reference point, the prescribing information for one oral option states that in general daily use for three months or more is necessary before benefit is observed. Judging any treatment in weeks is the most common self-inflicted failure in this category.
A temporary increase in shedding early in treatment is recognised with certain therapies and does not automatically mean the treatment is failing. It is still worth telling your clinician, because they can tell the difference between that and a problem, and you cannot.
Agree that at the start, with your clinician, and write it down. For many people the honest answer is that no further loss is a good outcome, because the alternative was continued progression. If nobody defines success at baseline, it gets redefined afterwards by whoever is disappointed.
Where a treatment is working, the benefit generally depends on continuing it. The prescribing information for one oral option states that withdrawal of treatment leads to reversal of the effect within a year. This is worth knowing before you start, not after, because it makes the decision a long-term one.
There is no cure and this page offers none. It is a long-running, largely inherited process that is managed rather than resolved. Realistic aims are slowing progression, maintaining what is there and, for some people, some regrowth — with no guarantee attached to any of it.
This is a question for your surgeon, and it is one of the more important ones. Surgery redistributes hair from areas that are usually less susceptible; it does not switch off the process in the hair that was not transplanted. Follow your surgeon's instructions and get specific clearance before introducing anything new to the scalp.
Same camera and lens, same distance, same room and light source, same time of day, hair dry and styled the same way, no flash and no filters. Take five views — front, part, crown and both temples — on a fixed interval. Consistency matters far more than image quality.
That is the normal position, and it is the reason assessment exists. A consultation will tell you which pattern you actually have before you spend anything.
Six sources. Every URL was checked against the publisher’s own site on 29 July 2026, and each one supports a claim this page actually makes. Where reliable evidence is unavailable, this page says so rather than filling the gap.
Describes the pattern of loss in men and women, states that variations in the AR gene appear to make androgen receptors more easily stimulated by androgens, and says plainly that it remains unclear how those genetic changes increase risk. Also records the association with polycystic ovary syndrome in women.
Separates shedding from loss — the distinction this page is built on. Supports the position that sudden diffuse shedding after illness, childbirth or stress is a different problem from patterned thinning.
Sets out how hereditary hair loss is diagnosed and what the treatment options are, including the point that not everyone responds and that more study is needed for several device-based approaches.
Notes that other causes of hair loss can look like female pattern hair loss and must be ruled out, and that dermatologists frequently combine more than one treatment.
The label used on this page for four things only: that this oral 5-alpha-reductase inhibitor is indicated in men and not indicated for use in women; that effectiveness could not be demonstrated in the postmenopausal women studied; that women who are or may become pregnant must not handle crushed or broken tablets; and that the molecule reduces DHT formation without binding the androgen receptor itself. US labelling; Indian products carry their own approved labelling.
A clinician-facing reference describing androgenetic alopecia as a genetically predetermined condition driven by an excessive response to androgens, and setting out the assessment and comorbidity screening that belongs with it.
How we evaluate evidence: manufacturer and regulator sources are read from the publisher’s own site rather than from marketplaces or aggregators; a claim that cannot be traced to a named source is not published; where sources disagree, the disagreement is published rather than resolved in favour of whichever is more convenient; and no DOI, trial, quotation, statistic or endorsement is ever invented. Note that the prescribing information cited here is US labelling. Products marketed in India carry their own approved labelling, which may differ, and regulatory status changes over time — this page is date-stamped for that reason. Read our evidence methodology, editorial policy and medical review policy.
The one step that changes everything else
Build a structured plan around your pattern, your scalp condition, your safety profile and the level of support you can actually sustain. Everything on this page is downstream of knowing what you have.
Your cart is empty